The World’s First Ovarian Tissue Dual-Activation Technology Selected into the 2025 "Shandong Outstanding Achievements Report" Project
Release time:
2025-10-13
According to recent announcements by the Jinan Municipal Bureau of Science and Technology, 11 outstanding achievements from Jinan have been included in the 2025 "Shandong Outstanding Achievements Report" project. Among them is the globally first-of-its-kind ovarian tissue dual-activation technology developed by Shandong Silver Med Life Science Research Institute (Jinan).
Addressing Infertility Challenges and Nurturing Hope for Childbearing
Shandong Silver Med Life Science Research Institute (hereinafter referred to as "Silver Med Institute") collaborated with a team led by Professor Wang Huiying and Dr. Jin Bo from Beijing University of Chinese Medicine Shenzhen Hospital to develop this "ovarian dual-activation" technology, marking another milestone in cryobiomedical science. By employing a "cryopreservation + PFC" dual-activation approach for ovarian tissue, the technology has enabled patients to achieve natural conception. To date, the first healthy baby born through this method has been delivered safely.
It is reported that this is the world’s first case of successful natural conception and live birth achieved by activating ovaries using this method. The application of this technology not only brings hope to patients with premature ovarian failure (POF) and infertility but also provides a brand-new solution for fertility preservation in female cancer patients of childbearing age.
World’s First Ovarian Dual-Activation Technology
The team innovatively combined the in vitro activation of primordial follicles (IVA) with autologous venous-derived cytokine (PFC) technology, offering safer, more effective, and personalized treatment options for patients with premature ovarian insufficiency (POI) and poor ovarian response (POR).
PFC technology involves concentrating, activating, and isolating various cell growth factors, cytokines, and related proteins from autologous venous blood using specialized methods, followed by standardized preparation processes such as lyophilization. Clinical studies have confirmed that these endogenous growth factors and cytokines can aid tissue regeneration, including activating dormant primordial follicles in the ovaries, promoting angiogenesis, and increasing ovarian volume.
For POI/POR patients, traditional methods struggle to activate and grow ovarian follicles. The team’s innovative IVA technology involves extracting a small sample of ovarian cortical tissue via laparoscopic surgery, combining it with cryopreservation and revival techniques, subjecting it to ex vivo cryogenic activation in the lab, and performing in situ transplantation approximately one hour later. This process softens and expands the atrophied ovarian tissue. Post-operative evaluations show improvements in ovarian volume, follicle count, and ovarian artery blood flow, with hormone levels returning to normal.
Cryogenic Technology Safeguards Female Fertility
Experts note that the ovarian dual-activation technology not only provides a safe and reliable new option for POI/POR patients but also offers choices for fertility preservation in cancer patients.
Current fertility preservation methods primarily include oocyte cryopreservation, embryo cryopreservation, and ovarian tissue cryopreservation. For males, sperm cryopreservation is the main approach. Among these, ovarian tissue cryopreservation and transplantation are internationally recognized as the most promising methods for fertility protection, serving as the sole option for prepubertal girls and childbearing-age women undergoing non-deferrable anticancer treatment.
Additionally, experts highlight the technology’s potential application in menopausal regulation. By cryopreserving ovarian tissue at a young age and transplanting it later in life, it may delay menopause, reduce reliance on hormone therapy, and slow aging.
Looking ahead, the Silver Med Institute will collaborate with Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) to deepen research on original technologies in "fertility preservation," aiming to establish a comprehensive fertility preservation system. By applying cryopreservation technology more broadly and effectively in clinical practice, they strive to contribute to building a fertility-friendly society.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
